This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sana Biotechnology has a new $50 million tool in its toolbox. Gene editing technology is a key component in developing engineered cells as medicines, and we are pleased to have the ability to use the Cas12b system as part of a number of our ex vivo engineered cell programs,” said Steve Harr , Sana’s president and CEO in a statement.
A biotech prize for turning chemicals into food On the biotechnology front, the Mars Society plans to offer an incentive prize for methods that use microbes to convert simple chemicals, such as methane or methanol, into food. “Ask it anything you want, and you get the answer in multiple personalities,” he said.
Under the agreement, Takeda has options to exclusively licenseprograms at the preclinical stage and will take products to the clinic and through commercialization. Immusoft’s most advanced therapeutic program is designed to treat a rare enzyme deficiency disorder, Hurler syndrome.
based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. Seattle Genetics CEO Clay Siegall. Seattle Genetics Photo). Merck will own about 2.9
The publicly traded Seattle biotech company hired investment bank SVB Securities to review potential alternatives including a sale, merger, asset divestiture or licensing. “It Seattle biotech company Good Therapeutics sold its IL-2 program to Roche for $250 million in September and later rebranded as Bonum Therapeutics.
The UW has licensed the exclusive rights of this intellectual property to the startup. This funding will allow us to build upon our promising preliminary data demonstrating detection of Alzheimer’s disease at its earliest stages and further our preclinical therapeutic program,” Daggett said in a statement.
He develops tools to help understand massive-scale genomic and biomedical data and has helped generate online learning programs that have enrolled more than 8 million people. I think there’s a lot of room for creativity, especially within the data, machine learning and AI space at the interface between biotechnology and data science.
Founded in 2018, Vouched helps companies verify the identity of customers and users by examining driver’s licenses and other forms of identification. Sana Photo) — Dhaval Patel joined Sana Biotechnology as executive vice president and chief scientific officer. It can provide fraud detection of a person in real-time.
Juno veterans went on to start or fill leadership positions at Sana Biotechnology, Lyell Immunopharma, Umoja Biopharma, Shape Therapeutics, GentiBio, Eliem Therapeutics, Genemod, Century Therapeutics, Silverback Therapeutics, Tune Therapeutics, Affini-T Therapeutics, and others. Sana Biotechnology. Photo courtesy of William Canestaro).
So you buy a processing unit design from somebody like Arm in the UK, who is very popular, and then maybe you need the USB interface, so you get a USB IP block, which you license. So you decide, “I want to build a controller chip.” Moderna, for example, had been working on it for a decade with $1 billion of private capital invested.
We organize all of the trending information in your field so you don't have to. Join 83,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content